Table 4.
Relapse-free survival among individual subgroups of patients receiving the same total number of rituximab courses
| Rituximab Course | Subjects with Two Courses (n=145) | Subjects with Three Courses (n=83) | Subjects with Four Courses (n=50) | Subjects with Five Courses (n=28) | Subjects with Six Courses (n=22) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Event (n) |
Median Time, (mo) (95% CI) |
Event (n) |
Median Time, (mo) (95% CI) |
Event (n) |
Median Time, (mo) (95% CI) |
Event (n) |
Median Time, (mo) (95% CI) |
Event (n) |
Median Time, (mo) (95% CI) |
|
| Course 1 | 128 | 10.7 (9.0 to 12.7) | 76 | 11.0 (8.4 to 12) | 42 | 9.0 (7.7 to 12.6) | 27 | 7.8 (5.7 to 9.3) | 21 | 7.9 (5.7 to 10) |
| Course 2 | 86 | 27.1 (22.2 to 36.9) | 76 | 13.0 (10.5 to 15) | 45 | 11.0 (7.5 to 12.7) | 25 | 8.0 (5.0 to 9.1) | 18 | 7.6 (4.8 to 10) |
| Course 3 | — | — | 44 | 24.0 (16.0 to NA) | 44 | 12.8 (10.5 to 17) | 22 | 11.8 (9.1 to 14.8) | 17 | 8.9 (6.5 to 12.0) |
| Course 4 | — | — | — | — | 26 | 21.8 (16.5 to NA) | 21 | 15.1 (10.2 to 18.1) | 14 | 9.3 (7.1 to 15.9) |
| Course 5 | — | — | — | — | — | — | 16 | 22.7 (15.6 to 34.2) | 16 | 11.5 (6.9 to 17.5) |
| Course 6 | — | — | — | — | — | — | — | — | 13 | 16.3 (10.3 to 25) |
| P Value | <0.001 | <0.001 | <0.001 | <0.001 | 0.04 | |||||